Bristol Myers Squibb releases Q3 2026 results
Item 2.02 Reports results, Item 7.01 Investor disclosure
- Form
- 8-K
- Filed
- Importance
- Major
- Accession
- 0000014272-26-000022
- Non-GAAP financial measures included in press release
- Presentation materials available on company website
- Exhibits 99.1 and 99.2 furnished with filing
Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.
The reading, claim by claim
- In a Form 8-K filed October 29, 2026, Bristol-Myers Squibb reported under Item 2.02 that it issued an Earnings Press Release that day announcing its financial results for the third quarter of 2026.
- The release is furnished as Exhibit 99.1.
- The press release says third quarter revenues increased 7% to $13.1 billion, and Growth Portfolio revenues increased 12% to $7.7 billion.
- Its table lists total revenues of $13,069 million, against $12,222 million in 2025.
- GAAP EPS was $1.05 and non-GAAP EPS was $1.35.
- The release also says the company is raising 2026 revenue guidance to a range of $49.75 billion to $50.25 billion.
- It updates its non-GAAP EPS range to $6.35 to $6.55, inclusive of a $(0.60) per share net impact from Acquired IPRD charges and licensing income.
- Under Item 7.01, the company says it posted a presentation on its website for its third quarter conference call and webcast at 8:00 a.m.
- It is furnished as Exhibit 99.2, and the filing says this information is not deemed 'filed' under Section 18 of the Exchange Act.
9 of 10 claims matched the filing text.
Not found in the filing text
- In its 10-Q for the quarter ended September 30, 2026, the company reported revenue of $13.1 billion, net income of $2.2 billion, a gross margin of 68.3% and a net margin of 16.5%.
For perspective, checked against its own source
From the 10-Q for the quarter ended September 30, 2026
- It showed a revenue change of +6.9% from a year earlier.
From the filing
Item 2.02 Results of Operations and Financial Condition.
Item 2.02 Results of Operations and Financial Condition.
On October 29, 2026, Bristol-Myers Squibb Company (the "Company") issued a press release (the "Earnings Press Release") on its website at www.bms.com announcing its financial results for the third quarter of 2026.1 A copy of the Earnings Press Release is furnished pursuant to this Item 2.02 as Exhibit 99.12 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. Other than the Earnings Press Release, the information contained in or connected to the Company's website is not deemed to be incorporated by reference in this Current Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
Item 7.01 Regulation FD Disclosure.
On October 29, 2026, the Company posted on its website at www.bms.com a presentation (the "Bristol Myers Presentation") on certain financial and operating initiatives available for viewing during the Company's conference call and webcast announcing its financial results for the third quarter of 2026 at 8:00 a.m.8 Eastern time. A copy of the Bristol Myers Presentation is furnished pursuant to this Item 7.01 as Exhibit 99.29 to this Current Report on Form 8-K and incorporated by reference herein in its entirety. The Earnings Press Release and the Bristol Myers Presentation include references to non-GAAP financial information. Reconciliations between the non-GAAP financial measures and the comparable GAAP financial measures and the reasons for the presentation of such non-GAAP financial measures, are available in the Earnings Press Release which is included as Exhibit 99.1 hereto. The Bristol Myers Presentation should be read in conjunction with the Earnings Press Release. The Company reserves the right to discontinue availability of the Bristol Myers Presentation from its website at any time.
Pursuant to General Instruction B.2. to Form 8-K, the information set forth in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1, and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 19349, as amended (the "Exchange Act"), or otherwise subject to the liabilities thereof, nor shall it be incorporated by reference into future filings by the Company under the Exchange Act or under the Securities Act of 1933, as amended, except to the extent specifically provided in any such filing. Additionally, the submission of the information set forth in this Item 7.01 is not deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely by Regulation FD.
Item 9.01 Financial Statements and Exhibits.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are furnished as part of this Current Report on Form 8-K:
Exhibit
No. Description
104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
BRISTOL-MYERS SQUIBB COMPANY
Dated: October 29, 2026
By: /s/ Amy Fallone
Name: Amy Fallone
Title: Senior Vice President and Corporate Secretary
PRESS RELEASE OF BRISTOL-MYERS SQUIBB COMPANY DATED OCTOBER 29, 2026
Exhibit 99.1
Bristol Myers Squibb Reports Third Quarter Financial Results for 2026 and Raises Full-Year Revenue Outlook
Growth Portfolio Performance and Disciplined Execution Drive Strong Financial Results
Key Pipeline Milestones Include Regulatory Approvals and Positive Registrational Data Across Multiple Therapeutic Areas
• Third quarter revenues increased 7% to $13.1 billion3
◦ Growth Portfolio revenues increased 12% to $7.7 billion3
(PRINCETON, N.J., October 29, 2026) – Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2026.
"We delivered another quarter of double-digit growth in our Growth Portfolio, which increased 12% and reflects the continued momentum across our diversified portfolio," said Christopher Boerner, Ph.D. , board chair and chief executive officer, Bristol Myers Squibb. "The approval of Zenbexus , the first-in-class CELMoD, brings a new class of treatment to market for patients with multiple myeloma and is one of several recent pipeline milestones. As we look forward to additional late-stage data in the near term, we remain focused on executing with discipline, investing where we see the greatest opportunity and strengthening the foundation for sustainable growth."
Third Quarter Results
$ in millions, except per share amounts 2026 2025 Change Change Excl. FX**
Acquired IPRD Charges and Licensing Income Net Impact on Earnings/(Loss) Per Share (0.58) (0.20) N/A N/A
*GAAP and Non-GAAP earnings/(loss) per share include the net impact of Acquired IPRD charges and licensing income.
**See "Use of Non-GAAP Financial Information".
1
THIRD QUARTER RESULTS *
• Growth Portfolio revenues of $7.7 billion increased 12%. Revenue growth was primarily driven by Opdivo Qvantig , Breyanzi , Reblozyl, Camzyos and Opdualag.
• Legacy Portfolio revenues of $5.4 billion increased 1%. Revenue growth was primarily driven by Eliquis , partially offset by expected continued generic impacts across the remainder of the Legacy Portfolio.
• Total revenues of $13.1 billion increased 7%.
◦ U.S. revenues of $9.1 billion increased 9%.
◦ International revenues of $4.0 billion increased 3%, or 4% Ex-FX.
*All comparisons are made versus the same period in 2025 unless otherwise stated.
THIRD QUARTER PRODUCT REVENUE HIGHLIGHTS (e)
($ amounts in millions) Quarter Ended September 30, 2026 % Change from Quarter Ended September 30, 2025
% Change from Quarter Ended September 30, 2025 Ex-FX**
U.S.
Int'l WW (d)
U.S.
Int'l
WW (d)
Int'l
WW (d)
Growth Portfolio
Other Growth Products (a)
261 470 731 6 % 16 % 12 % 17 % 13 %
Total Growth Portfolio
4,951 2,711 7,662 12 % 12 % 12 % 13 % 12 %
Legacy Portfolio
Other Legacy Products (b)
Other Revenue (c)
** See "Use of Non-GAAP Financial Information".
(a) Includes Abecma , Augtyro , Empliciti, Inrebic, Nulojix , Onureg , Zenbexus and royalty revenues, including royalties received from Merck on Winrevair .
(b) Includes other mature brands.
(c) Includes revenue hedging activities in 2026.
(d) Worldwide (WW) includes U.S. and International (Int'l).
(e) For the above table and all subsequent tables, certain totals may not sum due to rounding. Percentages have been calculated using unrounded amounts.
2
THIRD QUARTER COST & EXPENSES
The table below presents selected line-item information.
GAAP Non-GAAP**
Three months ended September 30, Three months ended September 30,
($ amounts in millions) 2026
2025
Change
2026
2025
Change
Cost of products sold
$ 4,146 $ 3,435 21% $ 4,133 $ 3,312 25%
Gross margin
68.3 % 71.9 % (360) bps 68.4 % 72.9 % (450) bps
Selling, general and administrative
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Gilead Sciences GILD public float $103.2B, Jun 30, 2025
- Vertex Pharmaceuticals VRTX public float $113.4B, Jun 30, 2025
- Zoetis ZTS public float $69.2B, Jun 30, 2025
- Pfizer PFE public float $138.0B, Jun 29, 2025
- Amgen AMGN public float $150.1B, Jun 30, 2025